Brief: Context Therapeutics Reports Third Quarter 2022 Operating And Financial Results
09/11/2022 22:23
Nov 9 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS® REPORTS THIRD QUARTER 2022 OPERATING
AND
FINANCIAL RESULTS
* CONTEXT THERAPEUTICS- CASH AND CASH EQUIVALENTS OF $39
MILLION
AS OF SEPTEMBER 30, 2022, EXPECTED TO PROVIDE RUNWAY INTO Q1
2024
* CONTEXT THERAPEUTICS- QTRLY NET LOSS PER COMMON SHARE,
BASIC AND
DILUTED $0.24
Source text for Eikon: ID:nGNX9qwybH
Further company coverage: CNTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202